Navigation Links
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:8/1/2014

SOUTH PLAINFIELD, N.J., Aug. 1, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of 67,700 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on July 31, 2014 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

Five of the stock option awards have an exercise price of $26.42 per share, the closing price of PTC's common stock on July 31, 2014. The remaining stock option awards have an exercise price of $27.74 per share, the closing price of the PTC stock on August 1, 2014. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and an additional 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter, subject to the employee's continued service with the Company through the applicable vesting dates.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

Logo - http://photos.prnewswire.com/prnh/20010919/PTCLOGO 


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
2. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
3. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
4. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
5. PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
6. Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
7. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
8. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
9. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
10. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
11. Echo Therapeutics Hires Product Development Management Executive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 /PRNewswire/ ... - Pipeline Review, H1 2016" is a report ... pipeline and helps strengthen R&D pipelines by identifying ... best-in-class products. Company Profiles discussed in ... Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... ... 2016 , ... Coast Dental Fort Stewart is celebrating its grand opening with ... Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, ... will have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer ... a procedure that involves one or both jaw bones. This surgery is performed to correct ...
Breaking Medicine News(10 mins):